News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

XOSPATA (gilteritinib) Available for Order at Biologics by McKesson

XOSPATA is FDA Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation CARY, N.C., December XX, 2018 — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Astellas Pharma US, Inc. to be in t… Read More

COPIKTRA (duvelisib) Available for Order at Biologics, Inc.

COPIKTRA is a Dual Inhibitor Approved for Treatment of Adult Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Relapsed or Refractory Follicular Lymphoma CARY, N.C., September 26, 2018—Biologics, McKesson’s independent oncology and complex care specialty pharmacy, has been selected by Verastem Oncology™ to be in the limited distribution network for COPIKTRA™ (duvelisib),… Read More

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.

CARY, N.C. (July 23, 2018) — Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) wit… Read More

Combination Therapy BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the Treatment of BRAF-mutant Melanoma, Available for Order at Biologics, Inc.

CARY, N.C. (June 29, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Array BioPharma, Inc. to be in the limited distribution network for the combination therapy BRAFTOVITM (encorafenib) and MEKTOVI® (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E… Read More

TAVALISSE (fostamatinib disodium hexahydrate) Approved by FDA, Available for Order at Biologics, Inc.

CARY, N.C. (May 29, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, announced today that it has been selected by Rigel Pharmaceuticals, Inc. to be in the limited distribution network for TAVALISSETM (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase(SYK) inhibitor for the treatment of thrombocytopenia in adult patients with chronic immun… Read More

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson & Johnson1 to be in the limited distribution network for ERLEADA™ (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer (NM-CRPC). The addition of this critica… Read More

Biologics, Inc. Joins MedImpact Direct Specialty Program’s Specialty Pharmacy Network

CARY, N.C. (January 25, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, is now contracted with MedImpact Healthcare Systems, Inc. (“MedImpact”) to dispense specialty prescriptions under the MedImpact Direct Specialty program. “We are pleased to provide pharmacy services to members on behalf of the MedImpact Direct Specialty program,” said… Read More

McKesson Specialty Pharmacy Solutions Announces New Role for Key Executive

CARY, NC — November 2, 2017 — McKesson Specialty Pharmacy Solutions is pleased to announce Paula Bickley as Vice President, Market Access. In this new role, Paula will be tasked with expanding payer contracts to provide broader access to treatment for specialty pharmacy patients. In doing so, Paula will focus heavily on identifying solutions to… Read More

CALQUENCE® (acalabrutinib) Approved for Previously-Treated Mantle Cell Lymphoma, Available for Order at Biologics, Inc.

CARY, N.C. (November 1, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be in the limited distribution network for CALQUENCE® (acalabrutinib), a new oral treatment for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. CALQUENCE is a highly selectiv… Read More

VERZENIO (abemaciclib) Approved for Treatment of Metastatic Breast Cancer, Available for Order at Biologics, Inc.

CARY, N.C. (October 10, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM (abemaciclib), Eli Lilly’s first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration (FDA) on September 28,… Read More